Genscript Biotech (1548) H2 2025 earnings summary

Executive summary

• Revenue rose 61.4% year-over-year to $959.5 million, with adjusted net profit up 285% to $230.3 million, driven by platform synergy, globalization, and innovative product launches.

• All business units—Life Science Group, ProBio, and Bestzyme—delivered sustainable growth, with ProBio showing the most significant surge.

• Gross profit increased 103.3% to $553.2 million.

• Net loss of $532.4 million was recorded, mainly due to share loss and impairment from Legend Group investment.

• Significant ESG progress, including MSCI ESG rating upgrade to AA and inclusion in FTSE4Good and S&P Global Sustainability Yearbook.

Financial highlights

• Revenue reached $959.5 million (+61.4% YoY); gross profit more than doubled to $553.2 million.

• Adjusted net profit was $230.3 million (+285% YoY); net loss was $532.4 million due to Legend Group impairment.

• Life Science Group revenue grew 14.8% to $522.1 million; ProBio revenue surged 309.1% to $388.7 million (including $280 million LaNova license deal); Bestzyme revenue up 7.9% to $58 million.

• Adjusted gross profit margin at 51.2%; adjusted operating profit at $95.4 million.

• Cash and bank balances plus wealth management products totaled $843.1 million (+14.3% YoY).

Outlook and guidance

• 2026 revenue growth guidance: Life Science Group 15–18%, ProBio services 25–30%, Bestzyme 10–15%.

• Adjusted gross margin expected to reach 52% for Life Science Group and 43% for Bestzyme.

• Focus on high-quality growth, profitability improvement, automation, digitalization, and global expansion.

• ProBio targets 20–25% fee-for-service revenue growth and aims for positive EBITDA by 2027.

• Maintains long-term strategic investment in Legend Group, optimistic about its future value.